Markets · 1 sources covering this

Shionogi-Backed Biotech Apnimed Raises $192 Million in US IPO

Apnimed Inc., a late-stage drug developer focused on sleep apnea, raised $192 million in an upsized US initial public offering, priced at the top of a marketed range.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

1 L · 0 C · 0 R

How 1 sources are covering this

BloombergLean L·2h ago
Shionogi-Backed Biotech Apnimed Raises $192 Million in US IPO
Apnimed Inc., a late-stage drug developer focused on sleep apnea, raised $192 million in an upsized US initial public offering, priced at the top of a marketed range.
Read at Bloomberg →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/502dbb47eea621d6e7bcc414d3d4eeb580ae53b1"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Shionogi-Backed Biotech Apnimed Raises $192 Million in US IPO"></iframe>

Shionogi-Backed Biotech Apnimed Raises $192 Million in US IPO

How 1 sources are covering this

Shionogi-Backed Biotech Apnimed Raises $192 Million in US IPO

More from Markets

Swiggy, Eternal Stocks Surge as Zepto’s India IPO Hits Roadblock

BOJ Holds Rate Steady And Upgrades View on Economy

PBOC’s Weaker Daily Fixing to Temper Yuan Gains, Analysts Say

Asian Stocks Post Biggest Gain in Four Months on AI Optimism

Reader

Trust & legal

Across the network